March 18, 2002
Phase I trial results suggest that Metastat (COL-3) is reasonably well tolerated and produces anti-tumor activity in subjects with AIDS-related Kaposi's Sarcoma (KS). The trial included 18 subjects - 17 had experienced recurrent disease following therapy with drugs such as liposomal daunorubicin, paclitaxel and liposomal doxorubicin. Additionally, 14 of the subjects were receiving highly active anti-retroviral therapy. Results showed that eight of 18 (44%) subjects experienced tumor regression with Metastat treatment. All signs of cancer were eliminated in one subject, and in seven subjects, at least a 50% decrease in the number or size of cancer lesions was observed. Metastat is being developed by CollaGenex Pharmaceuticals.